Clinical Trial Search

Primary: Feasibility (≥60% Enrollment Rate of Eligible Patients; ≥70% Survey Adherence; ≥80% FitBit Adherence) and Acceptability (≥60% Would Recommend the Intervention; <30% Rate…

Primary: Average Daily Opioid Use as Measured by the Morphine Milligram Equivalents (MME) Per Day — 32; 39 MME per day

Primary: Change in Global Composite Score for Cognitive Decline — -0.24; -0.25; -0.25; -0.24 Z-score — p=0.31

Primary: Change in Number of Nights Wet Per 2 Weeks — 11; 8.78; 8.75; 6.22 # nights wet over 2 weeks

Primary: Proportion (Number) of Eyes With Clinically Relevant Recovery of Visual Acuity From Baseline — 60 eyes — p=0.0021

Primary: Father Involvement as Measured by the Fragile Families Survey - Father Report — 41.1; 41.2; 41.6; 41.3 score on a scale — p=.962

Primary: Change From Baseline in Blood Pressure, as Measured by an Automated Oscillometric Blood Pressure Device. — -3.00; -6.67; -6.00; -7.67 mmHg

Primary: Change in CD4 Count From Baseline to Follow-up — -0.085; -0.024; -0.020; -0.090 log cells per mm^3

Primary: Change in Hepatic Lipogenesis — 5.6 abs percent change fasting lipogenesis

Primary: Species Richness — 11.0; 11.1 units on a scale — p=0.232

Primary: Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes — -1.13; -2.43; -3.37 Urgency episodes per day — p==0.1722

Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 9; 8; 16; 20 participants

Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies

Primary: Number of Participants With Local, Regional, and/or Distant Failure — 12 Participants

Primary: Serum NCC Concentration — 46.5; 58.7 µg/L